Follow The Filings

CRMD Cormedix Inc.

Health Care, filed as CORMEDIX INC (COM), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by CRMD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRMD insider trades
  • None no insider bought on the open market
  • $1.1M sold by 2 insiders outside a trading plan
  • $1.6M sold by 3 insiders under 10b5-1 plans
  1. Janet Dillione Director
    Planned sale
    $69K 10,000 shares at $6.88 21% of stake
    Traded Jan 21 Filed Jan 22
    ↗
  2. Alan W Dunton Director
    Planned sale
    $260K 20,000 shares at $13.00 33% of stake
    Traded Dec 30, 2025 Filed Jan 2
    ↗
  3. Joseph Todisco CEO
    Planned sale
    $360K 30,000 shares at $12.00 5.6% of stake
    Traded Dec 18, 2025 Filed Dec 19, 2025
    ↗
  4. Janet Dillione Director
    Planned sale
    $408K 34,000 shares at $12.00 41% of stake
    Traded Dec 9, 2025 Filed Dec 11, 2025
    ↗
  5. Steven W Lefkowitz Director
    Sale
    $475K 40,000 shares at $11.88 33% of stake
    Traded Dec 9, 2025 Filed Dec 10, 2025
    ↗
  6. Janet Dillione Director
    Planned sale
    $467K 46,657 shares at $10.00 49% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
    ↗
  7. Janet Dillione Director
    Sale
    $262K 26,343 shares at $9.93 35% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025
    ↗
  8. Janet Dillione Director
    Sale
    $343K 30,000 shares at $11.42 38% of stake
    Traded Nov 14, 2025 Filed Nov 18, 2025
    ↗
  9. Myron Kaplan Director
    Buy
    $276K 25,000 shares at $11.02 +14% to stake
    Traded Oct 23, 2025 Filed Oct 27, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 14 option exercises, and 12 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 4.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A PROXY STATEMENT Filing Doc
DEFA14A DEFINITIVE ADDITIONAL MATERIALS Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K ANNUAL REPORT Filing Doc

Source: SEC EDGAR submissions, updated 11 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Gross profit — $40.28M $275.75M
Net income -$46.34M -$17.93M $163.06M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $79.45M $114.58M $367.05M
Total non-current assets * $2.61M $4.27M $459.09M
Total assets $82.06M $118.85M $826.14M
Total current liabilities $11.4M $33.84M $174.27M
Total non-current liabilities * $0.517M $0.349M $246.57M
Total equity $70.14M $84.66M $405.31M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$38.41M -$50.61M $175.05M
Cash from investing -$17.06M $21.23M -$308.43M
Cash from financing $55.92M $26.32M $238.45M
Net change in cash $0.448M -$3.07M $105.07M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.